-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

SVB Securities Adjusts Fate Therapeutics Price Target to $10 From $62, Maintains Outperform Rating

SVB Securities Adjusts Fate Therapeutics Price Target to $10 From $62, Maintains Outperform Rating

MT Newswires · 01/06/2023 04:33